Rachana R. Maniyar
Research Subjects
Rachana R. Maniyar has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Taha Merghoub
Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, USA
22 shared publications - Jedd D. Wolchok
Parker Institute for Cancer Immunotherapy and Sandra and Edward Meyer Cance, Weill Cornell Medicine, New York, United States of America
14 shared publications - Alan N. Houghton
Memorial Sloan Kettering Cancer Center 3 New York, NY
13 shared publications - Allison Betof Warner
Stanford University School of Medicine, Stanford, California, USA
13 shared publications - Benjamin D. Greenbaum
Computational Oncology, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA
13 shared publications - Daniel Hirschhorn
Weill Cornell Medicine 1 New York, NY
13 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones
Supplementary Figure 2 | Immunophenotyping of tumor infiltrates in B16-F10 tumor bearing mice treated with combination therapy of CTX+αPD-1+αCTLA-4
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones
Supplementary Figure 2 | Immunophenotyping of tumor infiltrates in B16-F10 tumor bearing mice treated with combination therapy of CTX+αPD-1+αCTLA-4
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Data from Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones
Cancer treatment using immune checkpoint blockade (ICB) with anti–programmed cell death protein 1 (αPD-1) and anti–cytotoxic T lymphocyte–associated protein 4 (αCTLA-4) has been successful. However, primary and acquired resistance limits clinical benefit. To improve the effectiveness of ICB therapies, strategies that reorchestrate antitumor immunity through mechanism-based drug combinations are being actively explored. The alkylating chemotherapeutic agent cyclophosphamide (CTX) has direct tumoricidal and immunomodulatory properties, including the induction of homeostatic proliferation of T cells. As ICB suppresses inhibitory signals in T cells, we hypothesized that ICB could augment CTX-induced homeostatic proliferation of antigen-specific T cells, thereby resetting the T-cell receptor repertoire in favor of tumor-specific T cells. In this study, we showed that a single dose of CTX 1 day prior to starting αPD-1 + αCTLA-4 is sufficient to delay tumor progression in established melanoma and prolong survival in tumor-bearing mouse models. These effects extended to other lymphodepleting treatments, such as gemcitabine and radiotherapy. The antitumor immune response was mainly driven by the clonal expansion of activated/effector CD8+ tumor-infiltrating lymphocytes (TIL). Furthermore, combined CTX and αPD-1 + αCTLA-4 treatment demonstrated efficacy across additional preclinical tumor models, including colorectal cancer and triple-negative breast cancer. Overall, these findings highlight that the combination of CTX and ICB represents a clinically relevant approach in the treatment of immunotherapy-refractory tumors. Significance:Combining lymphodepleting chemotherapy with dual immune checkpoint blockade enhances clonal expansion of effector CD8+ tumor-infiltrating lymphocytes, delays tumor growth, and improves survival, offering a promising strategy for overcoming resistance to immunotherapy.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones
Cancer treatment using immune checkpoint blockade (ICB) with anti–programmed cell death protein 1 (αPD-1) and anti–cytotoxic T lymphocyte–associated protein 4 (αCTLA-4) has been successful. However, primary and acquired resistance limits clinical benefit. To improve the effectiveness of ICB therapies, strategies that reorchestrate antitumor immunity through mechanism-based drug combinations are being actively explored. The alkylating chemotherapeutic agent cyclophosphamide (CTX) has direct tumoricidal and immunomodulatory properties, including the induction of homeostatic proliferation of T cells. As ICB suppresses inhibitory signals in T cells, we hypothesized that ICB could augment CTX-induced homeostatic proliferation of antigen-specific T cells, thereby resetting the T-cell receptor repertoire in favor of tumor-specific T cells. In this study, we showed that a single dose of CTX 1 day prior to starting αPD-1 + αCTLA-4 is sufficient to delay tumor progression in established melanoma and prolong survival in tumor-bearing mouse models. These effects extended to other lymphodepleting treatments, such as gemcitabine and radiotherapy. The antitumor immune response was mainly driven by the clonal expansion of activated/effector CD8+ tumor-infiltrating lymphocytes (TIL). Furthermore, combined CTX and αPD-1 + αCTLA-4 treatment demonstrated efficacy across additional preclinical tumor models, including colorectal cancer and triple-negative breast cancer. Overall, these findings highlight that the combination of CTX and ICB represents a clinically relevant approach in the treatment of immunotherapy-refractory tumors. Significance:Combining lymphodepleting chemotherapy with dual immune checkpoint blockade enhances clonal expansion of effector CD8+ tumor-infiltrating lymphocytes, delays tumor growth, and improves survival, offering a promising strategy for overcoming resistance to immunotherapy.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones
Supplementary Figure 1| Combination of Cyclophosphamide with Immune Checkpoint Blockade drastically improves tumor control but induces memory only in a subset of mice
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones
Supplementary Figure 1| Combination of Cyclophosphamide with Immune Checkpoint Blockade drastically improves tumor control but induces memory only in a subset of mice
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones
Supplementary Figure 4 | Confirmation of CD4 and CD8 depletion in B16-F10 tumor bearing mice treated with combination therapy of CTX and ICB
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones
Supplementary Figure 4 | Confirmation of CD4 and CD8 depletion in B16-F10 tumor bearing mice treated with combination therapy of CTX and ICB
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones
Supplementary Figure 3 | Immunophenotyping of tumor infiltrates in B16-F10 tumor bearing mice treated with combination therapy of CTX+αPD-1+αCTLA-4.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones
Supplementary Figure 3 | Immunophenotyping of tumor infiltrates in B16-F10 tumor bearing mice treated with combination therapy of CTX+αPD-1+αCTLA-4.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones
Supplementary Figure 5 | CTX+αPD-1+ αCTLA-4 treatment does not affect CD4 T, NK, and humoral compartments
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones
Supplementary Figure 5 | CTX+αPD-1+ αCTLA-4 treatment does not affect CD4 T, NK, and humoral compartments
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones
Supplementary Figure 6 | CTX+αPD-1+ αCTLA-4 treatment does not affect myeloid cells
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones
Supplementary Figure 6 | CTX+αPD-1+ αCTLA-4 treatment does not affect myeloid cells
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones
Supplementary Figure 7 | CTX+αPD-1+αCTLA-4 does not change entropy of TIL populations
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones
Supplementary Figure 7 | CTX+αPD-1+αCTLA-4 does not change entropy of TIL populations
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones
Supplementary Figure 8 | CTX+αPD-1+ αCTLA-4 increases effector CD8 TIL clonality
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones
Supplementary Figure 8 | CTX+αPD-1+ αCTLA-4 increases effector CD8 TIL clonality
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones
Supplementary Figure 9 | TCR clonality and distribution across CD8 TIL phenotypes
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones
Supplementary Figure 9 | TCR clonality and distribution across CD8 TIL phenotypes